
Results
4
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
4 companies
argenx
Market Cap: €48.0b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€783.60
7D
1.5%
1Y
33.9%
Elia Group
Market Cap: €11.3b
Develops and operates as a transmission system operator in Belgium and Germany.
ELI
€104.00
7D
0.7%
1Y
26.2%
Groupe Bruxelles Lambert
Market Cap: €8.9b
Invests in a portfolio of industrial, consumer goods, and business service companies operating in various sectors in Belgium, other European countries, North America, and internationally.
GBLB
€73.80
7D
-1.1%
1Y
11.0%
UCB
Market Cap: €47.2b
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
UCB
€248.20
7D
3.6%
1Y
36.4%